- Home
- PCB vs ACIU Comparison
PCB vs ACIU Comparison
Compare PCB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- ACIU
- Stock Information
- Founded
- PCB 2003
- ACIU 2003
- Country
- PCB United States
- ACIU Switzerland
- Employees
- PCB N/A
- ACIU N/A
- Industry
- PCB Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- ACIU Health Care
- Exchange
- PCB Nasdaq
- ACIU Nasdaq
- Market Cap
- PCB 285.3M
- ACIU 332.4M
- IPO Year
- PCB N/A
- ACIU 2016
- Fundamental
- Price
- PCB $20.21
- ACIU $2.68
- Analyst Decision
- PCB Hold
- ACIU Strong Buy
- Analyst Count
- PCB 2
- ACIU 2
- Target Price
- PCB $22.00
- ACIU $12.00
- AVG Volume (30 Days)
- PCB 28.3K
- ACIU 132.5K
- Earning Date
- PCB 01-23-2025
- ACIU 11-05-2024
- Dividend Yield
- PCB 3.56%
- ACIU N/A
- EPS Growth
- PCB N/A
- ACIU N/A
- EPS
- PCB 1.68
- ACIU N/A
- Revenue
- PCB $94,833,000.00
- ACIU $48,505,404.00
- Revenue This Year
- PCB N/A
- ACIU $85.33
- Revenue Next Year
- PCB $10.34
- ACIU $80.69
- P/E Ratio
- PCB $12.04
- ACIU N/A
- Revenue Growth
- PCB N/A
- ACIU 4097200.00
- 52 Week Low
- PCB $14.50
- ACIU $2.25
- 52 Week High
- PCB $22.20
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- PCB 41.74
- ACIU 27.49
- Support Level
- PCB $19.09
- ACIU $2.62
- Resistance Level
- PCB $20.63
- ACIU $3.02
- Average True Range (ATR)
- PCB 0.60
- ACIU 0.15
- MACD
- PCB -0.25
- ACIU -0.05
- Stochastic Oscillator
- PCB 36.01
- ACIU 9.52
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.